Genmab A/S (GMAB)
After hours:
| Previous close | 31.28 |
| Open | 31.12 |
| Bid | 30.86 x 900 |
| Ask | 31.55 x 800 |
| Day's range | 31.12 - 31.82 |
| 52-week range | 27.74 - 47.50 |
| Volume | |
| Avg. volume | 826,447 |
| Market cap | 20.646B |
| Beta (5Y monthly) | 0.70 |
| PE ratio (TTM) | 32.93 |
| EPS (TTM) | 0.96 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 41.96 |
ZacksAbbVie (ABBV) Lymphoma Drug Gets FDA Breakthrough Therapy Tag
The FDA grants breakthrough therapy designation to AbbVie's (ABBV) Epkinly in follicular lymphoma indication. The EMA validates a regulatory filing seeking label expansion for the drug.
GlobeNewswireGenmab Announces Positive Regulatory Updates for Epcoritamab (EPKINLY®/TEPKINLY®) for the Treatment of Relapsed/Refractory Follicular Lymphoma
Media ReleaseCOPENHAGEN, Denmark; November 27, 2023 U.S. Food and Drug Administration (FDA) grants Breakthrough Therapy Designation (BTD) for epcoritamab-bysp for the treatment of relapsed or refractory (R/R) follicular lymphoma (FL) after two or more lines of systemic therapy European Medicines Agency (EMA) validates regulatory application for epcoritamab for the same indicationThe regulatory actions are supported by data from the phase 1/2 EPCORE™ NHL-1 trial Genmab A/S (Nasdaq: GMAB) today an
- GlobeNewswire
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
Company Announcement COPENHAGEN, Denmark; November 21, 2023 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) made by managerial employees and their closely associated persons. The company’s managerial employees and their closely associated persons have given Genmab A/S power of attorney on their behalf to publish tradin
